Ashton Thomas Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Ashton Thomas Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-37	Closed	-$38.9K	–	1545
2024 Q2	$38.9K	Buy	+37	New	+$35.9K	﹤0.01%	984
2021 Q4	–	Sell	-2,102	Closed	-$1.27M	–	462
2021 Q3	$1.27M	Buy	2,102 +183	+10%	+$114K	0.18%	127
2021 Q2	$1.07M	Buy	1,919 +39	+2%	+$19.8K	0.16%	153
2021 Q1	$890K	Buy	1,880 +261	+16%	+$127K	0.15%	161
2020 Q4	$782K	Buy	1,619 +1,240	+327%	+$669K	0.15%	176
2020 Q3	$212K	Buy	379 +50	+15%	+$30.3K	0.05%	244
2020 Q2	$205K	Buy	+329	New	+$187K	0.06%	220

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Ashton Thomas Private Wealth's REGN Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 37 shares — an estimated $38.9K sold.

Ashton Thomas Private Wealth first reported a position in REGN in Q2 2020 and held it in 7 quarters. The position peaked at $1.27M in Q3 2021. 1,391 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

Ashton Thomas Private Wealth reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Ashton Thomas Private Wealth sold 37 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $38.9K.
Ashton Thomas Private Wealth first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Ashton Thomas Private Wealth's Regeneron Pharmaceuticals position peaked at $1.27M in Q3 2021.
1,391 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.